Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25Progression of preclinical next-generation ...
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships wit ...
Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & Company Two lead programs in immuno-inflammation and immuno-oncology planned to enter IND-enabling ...
We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...
A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...
The S&P 500 (SNPINDEX: ^GSPC) is cooling off after rip-roaring gains of over 20% in both 2023 and 2024. The Nasdaq Composite ...
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
An estimated 6 to 17 percent of children have sleep-disordered breathing, ranging from snoring to sleep apnea, which can cause behavioral, neurocognitive, cardiovascular, and cardiometabolic issues. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback